TP53 and mantle cell lymphoma: Despite many prognostic markers including MCL international prognostic index (MIPI), proliferation marker Ki-67, deletion or mutation of TP53, deletion of cyclin dependent kinase 2A (CDKN2A), or blastoid morphology, a reliable marker of chemoresistance is not available at diagnosis [14,15,16,17,18].